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ABSTRACT
INTRODUCTION Fludarabine‑ or bendamustine ‑based upfront immunochemotherapy is the current 
standard of care in fit patients with chronic lymphocytic leukemia (CLL). These regimens are poorly 
tolerated by patients with comorbidities, for whom the obinutuzumab–chlorambucil combination became 
the recommended first ‑line treatment.
OBJECTIVES We aimed to analyze real ‑life experience with the obinutuzumab–chlorambucil combination 
as the frontline treatment in elderly and unfit patients.
PATIENTS AND METHODS The retrospective analysis included 86 elderly patients (median age, 74 years) 
with CLL and a significant burden of comorbidities, treated with obinutuzumab–chlorambucil as the front‑
line regimen. All patients had a Cumulative Illness Rating Scale score greater than 6 and/or creatinine 
clearance of 30 to 69 ml/min.
RESULTS Overall response rate at 2 months after treatment completion was 95.3%, with complete 
remission (CR) rate of 43% and partial remission (PR) rate of 52.3%. Stable disease rate was 4.7%. Pro‑
gressive disease was not observed after treatment completion. The median progression ‑free survival 
(PFS) was not reached after a median follow ‑up of 18 months; estimated PFS at 30 months was 62%. 
We observed 6 relapses (7%), 3 (3.5%) in patients obtaining CR, and 3 (3.5%) in those with PR after im‑
munochemotherapy. The most frequent adverse events were neutropenia and infusion ‑related reactions 
(IRRs). Grade‑3 neutropenia occurred in 11.6% of patients, and grade‑3 IRRs, in 2.3%. There were no 
adverse events of grade 4 or 5.
CONCLUSIONS Our data confirm that the obinutuzumab–chlorambucil combination is an effective and 
well ‑tolerated regimen in untreated CLL patients with comorbidities.
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to be administered the obinutuzumab–chloram‑
bucil regimen.
The burden of comorbidities was evaluated us‑
ing the CIRS,19,20 and CrCl calculated according to 
the Cockcroft–Gault formula. The inclusion cri‑
teria were based on ESMO recommendations1: 
a CIRS score greater than 6 and/or CrCl lower 
than 70 ml/min.19-21
Treatment Obinutuzumab was infused at a dose of 
1000 mg intravenously on days 1, 8, and 15 of cycle 
1 and on day 1 of cycles 2 to 6 (28 ‑day cycles), with 
the first infusion split over 2 days for patients’ safe‑
ty. Chlorambucil was administered orally at a dose 
of 0.5 mg/kg of body weight on days 1 and 15 of 
each cycle. Prophylaxis of infusion ‑related reactions 
included the use of intravenous premedication with 
acetaminophen (1000 mg/dose), dexamethasone 
(20 mg/dose), and clemastine (2 mg/dose). All pa‑
tients received supportive treatment as required, 
including adequate fluid intake and allopurinol for 
tumor lysis syndrome prevention with antibacteri‑
al (trimethoprim–sulfamethoxazole) and/or anti‑
viral (acyclovir) prophylaxis. Granulocyte colony‑
‑stimulating factor (G ‑CSF) was not used for pri‑
mary prophylaxis of neutropenia, but secondary 
prophylaxis was allowed according to local stan‑
dards. Drugs used in the treatment of comorbidi‑
ties were not an interfering factor and did not af‑
fect the outcome of obinutuzumab–chlorambucil 
therapy. Efficacy (response rate and PFS) and safety 
data were collected. Response to treatment was as‑
sessed 2 months after the end of therapy according 
to the IWCLL guidelines.18 Due to the short period 
of follow ‑up after the end of treatment, the min‑
imal residual disease results were not included in 
the current analysis and will be provided later. 
Adverse events (AEs) were classified according to 
the National Cancer Institute Common Terminol‑
ogy Criteria for Adverse Events, version 4.03.22
Ethical considerations This study was carried out 
in accordance with the Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for 
experiments involving humans. Informed con‑
sent was obtained from all subjects to partici‑
pate in the study.
Statistical analysis The impact of categorized pa‑
rameters on the response to treatment was as‑
sessed by the Pearson χ2 test. PFS, estimated by 
the Kaplan–Meier method, was defined as the time 
from treatment initiation to the last date on which 
the disease activity was assessed, including death 
for any reason. Follow ‑up was too short to achieve 
meaningful overall survival results. A multivariate 
analysis of factors predicting response to treat‑
ment, including cytogenetics and immunoglobulin 
variable region heavy chain (IGHV) gene mutation‑
al status, was also performed. Statistical analyses 
were performed using Statistica, version 10 (Stat‑
Soft, Kraków, Poland).
INTRODUCTION Chronic lymphocytic leukemia 
(CLL) is the most common type of leukemia di‑
agnosed in the Western world, with an incidence 
rate of 4.2/100 000 increasing to >30/100 000/
year above the age of 80 years.1 The median age 
at diagnosis is 72 years.1 In older CLL patients, co‑
morbidities compromising the effective treatment 
are the major problem, and chlorambucil alone re‑
mained for years the standard of care in frail pa‑
tients2.3,4 The introduction of purine analogue–
based regimens did not improve the outcome in 
this population,5-8 and fludarabine ‑based chemo‑
therapy proved to be too toxic.9 This is why, addi‑
tion of rituximab, an anti ‑CD20 monoclonal anti‑
body, to fludarabine and cyclophosphamide (FCR), 
while significantly increasing overall survival in 
physically fit patients,10,11 did not change the out‑
come for frail and elderly population.12 In a recent 
retrospective international multicenter study of 
CLL patients treated with the bendamustine and 
rituximab (BR) regimen as frontline therapy, a sig‑
nificant burden of comorbidities ( Cumulative Ill‑
ness Rating Scale [CIRS] score ≥7) was indepen‑
dently associated with shorter progression ‑free 
survival (PFS).13 According to the European Soci‑
ety for Medical Oncology guidelines, intensive im‑
munotherapy regimens like FCR and BR are rec‑
ommended in treatment ‑naive CLL patients with‑
out significant comorbidities, defined as creatinine 
clearance (CrCl) exceeding 70 ml/min and a CIRS 
score of 6 or less.1
Obinutuzumab, a second ‑generation mono‑
clonal antibody, combined with chlorambu‑
cil, was a breakthrough for unfit patients with 
CLL, increasing their overall survival and be‑
coming the current first ‑line standard of care.1 
Obinutuzumab is a  humanized, glycoengi‑
neered, type ‑2 anti ‑CD20 antibody, with en‑
hanced antibody ‑dependent cellular cytotox‑
icity activity. It demonstrated superior effica‑
cy compared with rituximab in a randomized 
phase ‑III clinical trial.14,15 Additionally, 2 net‑
work meta ‑analyses confirmed the superior ef‑
ficacy of the obinutuzumab–chlorambucil reg‑
imen to other treatment options for unfit CLL 
patients.16,17 The objective of this retrospective 
analysis was to evaluate the efficacy and safety 
of the obinutuzumab–chlorambucil regimen in 
newly diagnosed patients with CLL not eligible 
for intensive immunochemotherapy in routine 
clinical practice (real ‑life experience).
PATIENTS AND METHODS Patients In this ret‑
rospective analysis, we collected the data of CLL 
patients who were ineligible for intensive immu‑
nochemotherapy due to significant comorbidities 
and who received obinutuzumab and chlorambu‑
cil as the first ‑line therapy. Diagnosis of CLL, as 
well as indications for starting the treatment, was 
based on the International Workshop on Chron‑
ic Lymphocytic Leukemia (IWCLL) guidelines.18 
All patients fulfilled the inclusion criteria to start 
treatment according to the IWCLL guidelines and 
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was 8 (range, 4–14) and the median CrCl was 
64 ml/min. Most patients (94.2%) presented with 
4 or more comorbidities, with ischemic heart dis‑
ease, arterial hypertension, and endocrine or met‑
abolic disorders being the most frequent. At base‑
line, the assessment of the following genomic ab‑
errations was performed by fluorescence in situ 
hybridization (FISH) in 69 patients: deletion of 
the short arm of chromosome 17, del(17p); dele‑
tion of the long arm of chromosome 11, del(11q); 
deletion of the long arm of chromosome 13; and 
trisomy of chromosome 12. The analysis of IGHV 
mutation was performed in 52 patients.22,23 Un‑
favorable risk factors such as del(17p), del(11q), 
and unmutated IGHV genes were found in 10%, 
16%, and 56% of patients, respectively.
The median number of obinutuzumab and chlo‑
rambucil cycles was 6; only 1 patient (1.2%) dis‑
continued the therapy after the third cycle due 
to grade ‑3 infusion ‑related reaction (IRR). There 
were no dose reductions. The overall response 
rate at 2 months after completion of immuno‑
chemotherapy was 95.35%, with a complete re‑
mission (CR) rate of 43% and partial remission 
(PR) rate of 52.3%. Four patients (4.7%) had sta‑
ble disease and no progression during therapy. 
The median PFS was not reached after a medi‑
an follow ‑up of 18 months; the estimated PFS 
at 30 months was 62% (FIGURE 1). Relapse was ob‑
served in 6 patients (7%): 3 patients with CR and 
the other 3 with PR after chemoimmunothera‑
py. There were no significant differences in re‑
sponse rates in high ‑risk groups: del(17p) (42% 
CR, 57.1% PR), del(11q) (36.4% CR, 54.5% PR), 
or unmutated IGHV (37.9% CR, 55.2% PR). No 
deaths were observed during the treatment and 
follow ‑up. The relatively small number of patients 
in the study did not allow for any meaningful sub‑
group PFS analysis, but it should be noted that 
3 of the 7 patients with del(17p) had already made 
progress during the relatively short follow ‑up.
In the analyzed group, adverse events (AEs) 
of grade 2 and higher occurred in 45 patients 
(52.3%), including grade ‑2 AEs observed in 34 pa‑
tients (39.5) and grade ‑3 AEs in 15 patients 
(17.4%) (TABLE 2). Grade ‑3 neutropenia resolved 
completely and did not reappear when G ‑CSF 
was used as secondary prophylaxis. There were 
no episodes of febrile neutropenia. The most fre‑
quent AEs were neutropenia and infusion ‑related 
reactions. In 82.1% of patients (23/28), IRRs oc‑
curred only during the first infusion of mono‑
clonal antibody. Except for 1 patient, who dis‑
continued the treatment after the third cycle, 
no grade ‑3 IRRs were observed during subse‑
quent obinutuzumab infusions. The tumor lysis 
syndrome occurred in 4 patients (4.6%) and re‑
solved after hydration and treatment with ras‑
buricase. Two patients (2.3%) required hospital‑
ization related to AEs (infections). There were no 
AEs of grade 4 or 5. The details of AEs are sum‑
marized in TABLE 2.
RESULTS Between April 2015 and November 
2017, 86 consecutive patients with CLL were 
treated with obinutuzumab and chlorambucil in 
10 Polish Adult Leukemia Group (PALG) centers. 
Patient characteristics and demographic data are 
presented in TABLE 1. The median age at the start 
of treatment was 74 years (range, 51–86 years) 
with a male ‑to ‑female ratio of 1.15. All patients 
had a CIRS score greater than 6 and/or CrCl of 
30 to 69 ml/min.19 -21 The median CIRS score 
TABLE 1 Patient and disease characteristics at baseline
Parameter Value
Demographic and clinical data
Male sex, n (%) 47 (54.6)
Age, y, median (range) 74 (51–86)
Age ≥70 years, n (%) 63 (73.3)
ECOG PS, median (range) 1 (0–1)
CIRS score, median (range) 8 (4–14)
CIRS score ≥7, n (%) 70 (81.4)
CrCl, ml/min, median (range) 64 (35–95)
CrCl <70, ml/min, n (%) 55 (63.9)
Organ or system disorders
Cardiac, n (%) 62 (72.1)
Vascular, n (%) 59 (68.6)
Hypertension, n (%) 71 (82.6)
Eye, ear, throw or larynx, n (%) 19 (22.1)
Respiratory, n (%) 27 (31.4)
Upper gastrointestinal, n (%) 12 (13.9)
Lower gastrointestinal, n (%) 16 (18.1)
Hepatic or biliary, n (%) 21 (24.4)
Renal, n (%) 19 (22.1)
Genitourinary, n (%) 24 (28.9)
Endocrine or metabolic, n (%) 39 (45.3)
Musculoskeletal, n (%) 15 (17.4)
Neurologic, n (%) 7 (8.1)
Psychiatric, n (%) 6 (7.2)
Number of comorbidities, median (range) 4 (2–7)
Disease characteristics
Lymphocyte count ≥25×109/l, n (%) 74 (86.0)
Lymphocyte count ≥100×109/l, n (%) 30 (34.8)
Binet stage A, n (%) 10 (11.6)
Binet stage B, n (%) 50 (58.1)
Binet stage C, n (%) 26 (30.2)
Cytogenetics (n = 69)
17p deletion, n (%) 7 (10.1)
11q deletion, n (%) 11 (15.9)
Trisomy 12, n (%) 11 (17.4)
13q deletion, n (%) 18 (26.1)
Normal karyotype, n (%) 14 (20.3)
IGVH status (n = 52)
Unmutated, n (%) 29 (55.8)
Abbreviations: CrCl, creatinine clearance; CIRS, Cumulative Illness Rating Scale; ECOG 
PS, Eastern Cooperative Oncology Group Performance Status; IGVH, immunoglobulin 
heavy ‑chain variable ‑region gene
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and treatment ‑dose reduction was required in 
56% of the cases.26 The analysis of 555 elderly pa‑
tients with CLL enrolled in 2 trials with first ‑line 
treatment of fludarabine (with and without cyclo‑
phosphamide) or chlorambucil (CLL4 and CLL5) 
identified comorbidities as an independent pre‑
dictor of poor prognosis in terms of overall surviv‑
al.27 On the other hand, CLL was the major cause 
of death in patients with 2 or more comorbidities, 
suggesting the need for more efficient treatment 
but with a better safety profile.
The CLL11 study of the German CLL Study 
Group was the first clinical trial that was designed 
for unfit elderly patients with CLL. Obinutuzum‑
ab was approved by the European Medicine Agen‑
cy in 2014 for use in combination with chloram‑
bucil as a first ‑line therapy for CLL patients with 
comorbidities that make them unsuitable for 
full ‑dose fludarabine ‑based therapy. In Poland, 
obinutuzumab has been reimbursed since 2015, so 
the present report is the first Polish “real ‑world” 
analysis of the efficacy and safety of the obinu‑
tuzumab–chlorambucil regimen in clinical prac‑
tice. It addresses the increasingly debated issue 
of differences between the populations treated in 
clinical trials and in routine practice.
In the CLL11 study, chlorambucil—regarded 
a standard of care at that time—was compared 
with its combination with rituximab and obinu‑
tuzumab in treatment ‑naive CLL patients with 
coexistent conditions. The results for the obinu‑
tuzumab–chlorambucil regimen were superior to 
those of rituximab ‑chlorambucil, with the overall 
response rate of 58.4% vs 65.1%, including the CR 
rate of 20.7% vs 7% and almost doubled PFS (me‑
dian, 29 vs 15 months).28,29 In a retrospective 
analysis of the PALG, patient demographic data 
were similar to those in the CLL11 registration 
DISCUSSION Although the standard of care 
for physically fit patients with CLL was estab‑
lished nearly a decade ago, after the results of 
the CLL8 study were published,11 FCR is no lon‑
ger an optimal treatment for frail and elderly indi‑
viduals: in patients aged 65 years or older, the CR 
rate was 20%, as compared with 43% in young‑
er ones.24 There was no overall survival benefit 
observed in the elderly. In a study by Ferrajoli 
et al,25 FC and FCR were complicated by severe 
myelotoxicity and infections in 60% and 22% 
of patients, respectively, leading to early treat‑
ment discontinuation.25 The CLL10 study, com‑
paring the FCR to the BR regimen, also failed to 
demonstrate better CR rates (36% and 32%, re‑
spectively) with a median PFS of 48 months in 
patients older than 65 years.26 The less favorable 
outcomes of elderly patients treated with pu‑
rine analogue–based protocols were due to low 
adherence caused by the high incidence of AEs. 
The incidence of severe hematologic toxicities 
and infections was higher with both regimens 
in elderly patients. In patients treated with BR, 
grade ‑3 and ‑4 neutropenia and infections were 
noted in 61% and 26% of patients, respectively, 
FIGURE 1 Progression‑
‑free survival (PFS) in 
the study group. Blue 
circles denote complete 
observation.
TABLE 2 Safety analysis
Adverse events Grade 1 Grade 2 Grade 3 Grade 4
Infusion ‑related reactions 15 (17.5) 11 (12.8) 2 (2.3) 0
Neutropenia 17 (19.8) 19 (22.1) 8 (9.3) 0
Anemia 4 (4.6) 1 (1.2) 1 (1.2) 0
Thrombocytopenia 3 (3.5) 0 1 (1.2) 0
Tumor lysis syndrome 1 (1.2) 3 (3.5) 1 (1.2) 0
Infection 4 (4.6) 0 2 (2.3) 0
Data are presented as number (percentage) of patients.
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The relatively high incidence of reactions relat‑
ed to obinutuzumab infusion is possibly caused 
by rapid and profound B ‑cell depletion and cy‑
tokine release due to recruitment and activation 
of immune effector cells.14,33 In our analysis, we 
observed significantly fewer allergic reactions to 
obinutuzumab infusion: grade ‑3 IRRs or higher 
were observed in 2.3% of cases, compared with 
21% in the CLL11 trial. Again, this could be at‑
tributed to the enhanced premedication protocol.
The PALG study has limitations related to its 
retrospective design and the limited availability 
of data on the IGHV mutational status and cy‑
togenetic/FISH tests. This reflects clinical prac‑
tice in Poland, where the IGHV mutational sta‑
tus is evaluated only in a few hematology centers, 
since it does not influence therapeutic decisions. 
Similarly, cytogenetic/FISH tests for identifying 
high ‑risk patients are usually only performed in 
relapsed or refractory cases, because alternative 
drugs, including Bruton kinase inhibitors, are not 
available in Poland for patients on first‑line treat‑
ment. There is also no historical control group, 
since CIRS scores have only recently been imple‑
mented in Poland, and patients were not stratified 
according to comorbidities in previous analyses.
In conclusion, the data from this retrospective 
analysis confirm the high efficacy and safety of 
obinutuzumab ‑based therapy in routine clinical 
practice. Longer follow ‑up, together with planned 
minimal residual disease analysis, will provide ad‑
ditional information on the real ‑life effectiveness 
and safety of this new standard of first ‑line treat‑
ment in CLL patients who are not eligible for in‑
tensive fludarabine ‑based immunochemotherapy.
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trial, with a median age of 74 years (63% of pa‑
tients >70 years), a median CIRS score at base‑
line of 8, and similar rates of unfavorable cytoge‑
netic and molecular aberrations. Our results con‑
firmed the high efficacy of obinutuzumab–chlo‑
rambucil: we observed similar overall response 
rates and even an increased proportion of CR 
(43%) compared with the registration trial.28,29 
This may be partially due to less stringent meth‑
ods of response evaluation in clinical practice 
based on IWCLL criteria.18 Computed tomogra‑
phy and bone marrow biopsy are recommended 
for CR confirmation in clinical studies, while ul‑
trasound imaging remains the preferred meth‑
od in clinical practice.18 Similar results with high‑
er CR rates as compared with a clinical trial30,31 
were also reported in an observational study by 
Laurenti et al,32 who evaluated rituximab–chlo‑
rambucil as the first ‑line regimen in unfit pa‑
tients with CLL. The other possible explanation 
is a lower number of patients with obinutuzum‑
ab dose reductions and therapy discontinuation 
in the PALG analysis. In the CLL11 trial, obinu‑
tuzumab was discontinued due to IRR in 7% of 
patients compared with 1.2% in the PALG analy‑
sis, while treatment had to be reduced or delayed 
in 36% and 0% of patients, respectively. This was 
probably due to enhanced obinutuzumab premed‑
ication, based on intravenous dexamethasone, 
acetaminophen, and clemastine, originally used 
only in a subgroup of CLL11 trial patients, after 
protocol amendment.
None of the patients in the PALG analysis pro‑
gressed during therapy; in the median follow ‑up 
of 18 months, only 4 patients (4.7%) required 
second ‑line treatment. The good response rate 
was further confirmed by prolonged estimat‑
ed PFS (62% at 30 months), also longer than in 
the CLL11 study (26.7 months). In the CLL8 tri‑
al, estimated PFS at 3 years was 68% in patients 
aged 65 years or older without significant comor‑
bidities and normal renal function. It is surpris‑
ing that in the PALG analysis the response rates 
in patients with del(17p) were similar to those ob‑
served for the whole group; however, there were 
only 7 patients with del(17p), and 3 of them had 
already progressed despite response to treatment.
In our analysis, obinutuzumab–chlorambucil 
was well tolerated with a lower number of AEs (of 
any grade) compared with the registration study. 
This could be due to a smaller percentage of pa‑
tients with high CIRS scores: in the PALG study, 
the maximum CIRS score was 14, compared with 
20 in the CLL11 trial. We also observed a lower in‑
cidence of grade ‑3 neutropenia or higher, possibly 
due to efficient secondary prophylaxis with G ‑CSF. 
No febrile neutropenia or serious grade ‑4 AEs 
were noted during the treatment or follow ‑up af‑
ter the therapy. In addition, no deaths were re‑
ported. Autoimmune cytopenias are a common 
complication of CLL; therefore, the higher dose 
of steroids used in premedication in our study 
may account for the lower rates of anemia and 
thrombocytopenia.
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